vandortuzumab vedotin vandortuzumab vedotin vandortuzumab vedotin (inn; development code rg7450) is a humanized monoclonal antibody designed for the treatment of cancer. vandortuzumab vedotinmonoclonal antibodytypewhole antibodysourcehumanized (from mouse)targetsteap1clinical dataother namesrg7450atc codenoneidentifierscas number1471985-92-8chemspidernoneunii44ouq00d1ukeggd11002chemical and physical dataformulac6608h10168n1756o2076s44molar mass148838.89 g·mol−1 this drug was developed by genentech/roche. development was discontinued in 2017.